


**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

Express Mail Label No.: EL 796955496 US Date of Deposit: December 6, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, Virginia, 22202.

  
Tami M. Procopio

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the application of:

Daniel E.H. AFAR, *et al.*

Serial No.: Continuation of 09/323,873

Filing Date: Even Date Herewith

For: NOVEL SERPENTINE  
TRANSMEMBRANE ANTIGENS  
EXPRESSED IN HUMAN CANCERS  
AND USES THEREOF

Examiner: Not Assigned

Group Art Unit: Not Assigned

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Prior to examination of the application herein, please amend the specification as follows:

Please change the title of the application to read --PEPTIDES DERIVED FROM  
STEAP1--.

Please insert in the specification, under the title

--This application is a Continuation of U.S. Serial No. 09/323,873 filed 1 June 1999 and  
now allowed. The contents of this application are incorporated herein by reference.--

Please amend the claims as follows:

Please cancel claims 1-39 and substitute the following claims:

40. (New) A peptide selected from the group consisting of

a peptide consisting of the amino acid sequence WKMKPRRNLEEDDYL

(positions 14-28 of SEQ. ID. NO: 2);

a peptide having the amino acid sequence REVIHPLATSHQQYFYKIPILV (SEQ. ID.

NO: 19, positions 92-113 of SEQ ID NO: 2);

a peptide having the amino acid sequence

RRSYRYKLLNWAYQQVQQNKEDAWIEHDVWRMEI (SEQ. ID. NO: 20, positions 185-218 of SEQ ID NO: 2); and

a peptide having the amino acid sequence WIDIKQFVWYTPPTF (SEQ. ID. NO: 21, positions 277-291 of SEQ ID NO: 2).

41. (New) The peptide of claim 40 which is a peptide consisting of the amino acid sequence WKMKPRRNLEEDDYL (positions 14-28 of SEQ. ID. NO: 2).

42. (New) The peptide of claim 40 which is a peptide having the amino acid sequence REVIHPLATSHQQYFYKIPILV (SEQ. ID. NO: 19, positions 92-113 of SEQ ID NO: 2).

43. (New) The peptide of claim 40 which is a peptide having the amino acid sequence RRSYRYKLLNWAYQQVQQNKEDAWIEHDVWRMEI (SEQ. ID. NO: 20, positions 185-218 of SEQ ID NO: 2)

44. (New) The peptide of claim 40 which is a peptide having the amino acid sequence WIDIKQFVWYTPPTF (SEQ. ID. NO: 21, positions 277-291 of SEQ ID NO: 2)

45. The peptide of claim 40 further comprising a heterologous peptide.

46. The peptide of claim 40 labeled with a detectable marker.

47. A composition comprising the peptide of claim 40 and a carrier.

## REMARKS

The present application is directed to specific fragments of the STEAP1 protein, claims to which were allowed in the parent application herein. A terminal disclaimer with respect to the parent application is enclosed.

Support for the peptides of claim 40 is found as follows: support for the peptide at positions 14-28 of SEQ ID NO: 2 is found on page 41 of the specification at line 19. This peptide was used to generate antibodies immunospecific for STEAP1. Support for the remaining three peptides is found on page 20, lines 19-22 which states that preferred antibodies useful for cancer therapy are those that react with an epitope and extracellular region of the STEAP protein in combination with Figure 1B which shows positions 92-113; 185-218; and 277-291 as extracellular regions. This is further spelled out on page 22, lines 35-37.

The dependent claims parallel those allowed in the parent. No new matter has been added.

It is believed the claims as proposed are in a position for immediate allowance. Consideration of these claims and passage of these claims to issue is respectively requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 511582001601.

Respectfully submitted,

Dated: December 6, 2001

By: Kate H. Murashige  
Kate H. Murashige  
Registration No. 29,959

Morrison & Foerster LLP  
3811 Valley Centre Drive, Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5112  
Facsimile: (858) 720-5125